You are here

Antibiotic Use Can Be Cut by Half for Abdominal Infections, Study Shows

Findings suggest way to slow spread of ‘superbugs’

In a finding important for preventing the development of antibiotic-resistant “superbugs,” researchers at the University of Virginia (UVA) School of Medicine and 22 other institutions in the U.S. and Canada have determined that the duration of antibiotic treatment for complicated abdominal infections can be cut by half and remain equally effective.

The researchers, led by the UVA team, looked at the treatment of infections after the source of the infection was addressed, such as the removal of an inflamed appendix. They found that administering antibiotics for only 4 days was as effective as treatments spanning 8 days.

“There hasn’t been a lot of guidance on how long to treat intra-abdominal infections with antibiotics once you've gotten control over the source of infection,” said Christopher Guidry, MD, of the UVA Department of Surgery. “In the large scale, antibiotics have some downsides. The increasing prevalence of antibiotic resistance is a problem, so anything we can do to minimize exposure is important.”

The researchers set out to provide an answer to an important and unresolved question: How long a course of antibiotics is really necessary? An estimated 300,000 cases of appendicitis occur in the U.S. each year, and there are at least twice that many other cases of abdominal infection, so it is critically important that doctors have reliable information for providing treatment that is both effective and conservative in its antibiotic use, the authors said.

Doctors traditionally have given antibiotics until all symptoms disappear –– typically a week or two. More recent guidelines have called for much-shorter courses of 4 to 7 days, but many doctors have resisted the change and have continued to administer antibiotics for much longer –– 10 to 14 days.

The Study to Optimize Peritoneal Infection Therapy (STOP-IT) looked at 517 patients in the U.S. and Canada who had an abdominal infection. After their source infections were addressed, half were given antibiotics until 2 days after the resolution of fever, leukocytosis, and ileus, whereas the other half were given antibiotics for only 4 days.

The outcomes were similar between the two groups. Surgical-site infection, recurrent intra-abdominal infection, or death occurred in 21.8% (56/257) of the experimental group compared with 22.3% (58/ 260) of the control group (absolute difference, −0.5 percentage point; P = 0.92). The median durations of antibiotic therapy were 4.0 days in the experimental group and 8.0 days in the control group (absolute difference, −4.0 days; P < 0.001).

The results were published online in the New England Journal of Medicine.

“It’s important for physicians to realize that the most important aspect of the management of these patients is controlling the source of infection,” said Robert Sawyer, MD, of the UVA departments of surgery and anesthesiology. “These data certainly suggest that if a good operation is performed, a short course of antibiotics may be all that is required.”

Sarah Dunsmore, PhD, manages sepsis-related grants for the National Institutes of Health’s National Institute of General Medical Sciences, which funded the trial. “This is good news for patients at risk of developing sepsis –– and for the rest of us,” Dunsmore said. “It suggests that, in many cases, abdominal infections can be controlled much more quickly than expected. The STOP-IT trial essentially cut in half the length of antibiotic treatment, meaning fewer side effects for patients and dramatically lower costs.”

Sources: EurekAlert; June 8, 2015; and NEJM; May 21, 2015.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug